STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
The drug stabilized kidney function and reduced the risk of death and other complications in IgAN patients
Vera Therapeutics announced on Tuesday that their recently approved drug Trutakna demonstrated strong results in a Phase 3 clinical trial for patients with IgA nephropathy, a chronic autoimmune kidney disease. The two-year study showed that Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications.
Following the FDA's accelerated approval in July for treating IgAN, which leads to progressive kidney function loss and potentially organ failure requiring dialysis, Vera plans to seek full approval of the drug during the fourth quarter.
Brief written by urgent.news from STAT News's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
